Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.45Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -41.32%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical efficacy, U.S. market readiness, and international expansion. However, increased operating losses and changes in revenue recognition that impact short-term financial performance were noted. The company's strong cash position supports its strategic initiatives.Company Guidance
During the Nyxoah Fourth Quarter 2024 Earnings Conference Call, significant guidance was provided regarding the company's operations and future outlook. Nyxoah is poised to launch its Genio system in the U.S., having demonstrated strong clinical outcomes in its DREAM study, including a 63.5% AHI responder rate and a 71.3% ODI responder rate, with an overall median AHI reduction of 70.8%. The study also highlighted Genio's efficacy across different sleep positions, showing a 66.6% median AHI reduction in supine position. A notable 82% of subjects became "super responders," reducing their AHI scores to below 15. The company has deferred €600,000 in revenue related to disposable patches, with recognized revenue amounting to €1.3 million for Q4 and €4.5 million for the year. Nyxoah's cash position at year-end was €85.6 million, bolstered by a €24.6 million equity raise. The company anticipates FDA approval by the end of March 2025, supported by an existing CPT code (64568) for reimbursement, and has prepared a 50-member U.S. commercial team for launch.Genio's Efficacy in Treating OSA
The DREAM study met both its primary and secondary endpoints with a strong AHI responder rate of 63.5% and an ODI responder rate of 71.3%. The study demonstrated a 70.8% median AHI reduction, with Genio uniquely maintaining its efficacy irrespective of a patient's sleeping position.
U.S. Market Launch Preparation
Nyxoah is prepared for a U.S. market launch with a trained team of 50 commercial members and identified CPT code 64568 for reimbursement. The company expects to receive FDA approval by the end of March 2025.
Expansion in Europe and Beyond
The company launched Genio in the United Kingdom and the United Arab Emirates, with promising initial results. Revenue in Europe grew by 18% over 2023, reaching €5.1 million for the full year 2024.
Strong Cash Position
Nyxoah's cash position remained strong at €85.6 million at December 31, 2024, compared to €57.7 million at the end of 2023, including proceeds from a €24.6 million ATM equity raise.
---
NYXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NYXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $9.73 | $10.05 | +3.29% |
| Nov 06, 2024 | $10.00 | $9.64 | -3.60% |
| Aug 06, 2024 | $7.88 | $8.24 | +4.57% |
| May 14, 2024 | $9.58 | $10.27 | +7.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nyxoah (NYXH) report earnings?
Nyxoah (NYXH) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Nyxoah (NYXH) earnings time?
Nyxoah (NYXH) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NYXH EPS forecast?
NYXH EPS forecast for the fiscal quarter 2025 (Q1) is -0.52.
---